Evaluation of the effect of levothyroxine in subclinical hypothyroidism

Evaluation of the effects of levothyroxine treatment on fat profile and adult thyroid tests with subclinical hypothyroidism referred to Imam Hossein Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200731048259N1

Enrollment

Registered

2021-12-20

Start date

2021-12-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical hypothyroidism. Sub clinical iodine-deficiency hypothyroidism

Interventions

Intervention group: In the intervention group, levothyroxine (made by Iran Hormone Pharmaceutical Company) is used. This drug is in the form of 50 microgram tablets and is taken daily as a tablet for

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: People who have normal T4 and high TSH in their blood tests

Exclusion criteria

Exclusion criteria: Taking anti thyroid drugs and lithium Treated with radiation therapy or thyroid surgery Iodine deficiency Pregnancy Central disorder (pituitary gland)

Design outcomes

Primary

Measure	Time frame
Percentage of people whose lipid profile is affected by levothyroxine treatment. Timepoint: At the beginning of the study And 7 days later and 3 and 6 months after taking levothyroxine. Method of measurement: Laboratory data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyede Tahere Mirsamadi

Shahid Beheshti University of Medical Sciences

sarajm13@gmail.com+98 13 4275 3404

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026